DEF 14A: Geron Corporation Schedules 2024 Annual Stockholders Meeting, Outlines Key Proposals

Geron Corporation will hold its annual stockholders meeting virtually on May 9, 2024, to vote on director elections, executive compensation, and auditor ratification.

Summary

• Geron Corporation will hold its 2024 Annual Meeting of Stockholders virtually on May 9, 2024, at 5:00 p.m. Eastern Daylight Time.
• Stockholders will vote on the election of three Class I director nominees, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting FOR all director nominees, FOR the approval of executive compensation, and FOR the ratification of Ernst & Young LLP.
• The record date for determining stockholders eligible to vote at the Annual Meeting was March 12, 2024.
• The proxy materials are primarily available online, with instructions provided to stockholders on how to access them and vote electronically.
• Stockholders can vote online, by telephone, or by mail, with specific deadlines for each method.
• The Board has set corporate governance guidelines that include diversity considerations for director nominations.
• The company's executive compensation program is designed to align executive interests with those of stockholders, emphasizing pay for performance.
• The Audit Committee has pre-approved all services provided by Ernst & Young LLP in 2023 and 2022.
• Total fees paid to Ernst & Young LLP were $1,540,813 for the fiscal year ended December 31, 2023, and $950,475 for the fiscal year ended December 31, 2022.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing factual information about the upcoming annual meeting and related proposals. The forward-looking statements are balanced with risk disclosures, resulting in a moderately positive sentiment.

Positives

• The company is committed to good corporate governance practices.
• The Board emphasizes diversity in director nominations.
• The executive compensation program is designed to align executive interests with stockholder value creation.
• The Audit Committee is actively involved in overseeing the company's financial reporting and auditing processes.
• The company has a clawback policy in place for incentive compensation.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties.
• These risks and uncertainties could cause actual results to differ materially from those in such forward-looking statements.
• These risks and uncertainties include, without limitation, risks and uncertainties related to: (i) whether the United States Food and Drug Administration (FDA) or the European Medicines Agency may have issues with Gerons marketing applications for imetelstat for transfusion-dependent lower-risk MDS that delay or prevent approval and a potential commercial launch; (ii) whether Geron will be able to continue to develop imetelstat or advance imetelstat to subsequent clinical trials, or that Geron will be able to receive regulatory approval for or successfully commercialize imetelstat, on a timely basis or at all; (iii) whether imetelstat may cause, or have attributed to it, adverse events that could further delay or prevent the commencement and/or completion of clinical trials, delay or prevent its regulatory approval, or limit its commercial potential; (iv) whether the IMpactMF Phase 3 trial for relapsed/refractory MF has a positive outcome and demonstrates safety and effectiveness to the satisfaction of the FDA and international regulatory authorities, and whether Gerons projected rates for enrollment and death events differ from actual rates, which may cause the interim and final analyses to occur later than anticipated; (v) whether Geron overcomes all of the enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing and regulatory challenges in order to have the financial resources for, and to meet the expected timelines and planned milestones; (vi) if imetelstat is approved for marketing and commercialization, whether Geron is able to establish and maintain effective sales, marketing and distribution capabilities, obtain adequate coverage and third-party payor reimbursement, and achieve adequate acceptance in the marketplace; (vii) whether imetelstat actually demonstrates disease-modifying activity in patients; (viii) whether there are failures in manufacturing or supplying sufficient quantities of imetelstat that would delay, or not permit, the anticipated commercial launch or not enable ongoing or planned clinical trials; (ix) whether Geron is able to obtain and maintain the exclusivity terms and scopes provided by patent and patent term extensions, regulatory exclusivity, and have freedom to operate; (x) that Geron may be unable to successfully commercialize imetelstat due to competitive products, or otherwise; (xi) that Geron may decide to partner and not to commercialize independently in the U.S. or in Europe and other international markets; (xii) whether Geron has sufficient resources to satisfy its debt service obligations and to fund its planned operations; (xiii) that Geron may seek to raise substantial additional capital in order to complete the development and commercialization of imetelstat and to meet all of the expected timelines and planned milestones, and that Geron may have difficulty in or be unable to do so; and (xiv) the impact of general economic, industry or political climate in the U.S. or internationally and the effects of macroeconomic conditions on Gerons business and business prospects, financial condition and results of operations.

Future Outlook

The company anticipates a potential U.S. commercial launch of imetelstat, pending FDA approval, with a PDUFA date of June 16, 2024. Review of the imetelstat MAA in Europe is expected to be completed in early 2025, with a potential EU commercial launch in 2025. Interim analysis from the Phase 3 IMpactMF trial in R/R MF is expected in the first half of 2025, with a final analysis expected in the first half of 2026.

Management Comments

• John A. Scarlett, M.D., Chairman of the Board, President and Chief Executive Officer, expresses gratitude for stockholders' ongoing support and interest in Geron Corporation.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including proxy solicitations, director elections, executive compensation disclosures, and auditor ratification, all within the context of the biotechnology and pharmaceutical industry.

Comparison to Industry Standards

• The peer group used for executive compensation benchmarking includes companies like ADMA Biologics, ImmunityBio, and Mirati Therapeutics, reflecting a focus on similar-sized biopharmaceutical companies.
• The executive compensation program's structure, with a mix of base salary, performance-based bonuses, and equity incentives, aligns with industry norms for incentivizing and retaining key talent.
• The severance and change in control benefits provided to executives are consistent with those offered by comparable companies in the life sciences industry.
• The Audit Committee's oversight of the independent auditor and the pre-approval of services are standard practices for ensuring auditor independence and financial reporting integrity.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are provided with information to make informed decisions regarding director elections, executive compensation, and auditor ratification.
• Employees are impacted by the company's compensation and benefits programs, as well as its commitment to diversity and inclusion.
• Customers (potential patients) may benefit from the company's efforts to develop and commercialize new therapies.
• The company's suppliers and creditors are impacted by its financial performance and strategic decisions.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will proceed with preparations for the Annual Meeting on May 9, 2024.
• The company will continue to prepare for the potential commercial launch of imetelstat, pending regulatory approval.
• The company will continue to advance its clinical development programs, including the IMpactMF and IMproveMF trials.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Executive Compensation, Director Election, Ernst & Young, Audit Committee, Stockholders, Corporate Governance, Imetelstat